HT
FDMT icon

Headlands Technologies’s 4D Molecular Therapeutics FDMT Stock Holding History

Headlands Technologies’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$149K Buy
+15,956
New +$139K 0.02% 635

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Headlands Technologies's FDMT Position: Q1 2026 in Review

Headlands Technologies opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 15,956 shares worth $149K. The stake represents 0.02% of the portfolio and ranks #635 among its holdings.

152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Headlands Technologies held 15,956 shares of 4D Molecular Therapeutics worth $149K as of Q1 2026.
  • 4D Molecular Therapeutics was a new Headlands Technologies position in Q1 2026.
  • 4D Molecular Therapeutics made up 0.02% of Headlands Technologies's portfolio in Q1 2026, its #635 holding.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.